• +1-646-491-9876
    • +91-20-67278686

    Search

    E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Pipeline Review, H2 2016

    E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Pipeline Review, H2 2016

    • Report Code ID: RW0001499774
    • Category Pharmaceuticals
    • No. of Pages 66
    • Publication Month Nov-16
    • Publisher Name Global Markets Direct
    E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Pipeline Review, H2 2016

    Summary

    Publisher's, 'E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Pipeline Review, H2 2016', provides in depth analysis on E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted pipeline therapeutics.

    The report provides comprehensive information on the E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics development and features dormant and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

    Note:
    *Certain sections in the report may be removed or altered based on the availability and relevance of data.
    *Updated report will be delivered in 48 hours of order confirmation.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)
    - The report reviews E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics and enlists all their major and minor projects
    - The report assesses E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents

    List of Tables 5
    List of Figures 5
    Introduction 6
    Publisher Report Coverage 6
    E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Overview 7
    Therapeutics Development 8
    E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Products under Development by Stage of Development 8
    E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Products under Development by Therapy Area 9
    E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Products under Development by Indication 10
    E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Pipeline Products Glance 12
    Late Stage Products 12
    Early Stage Products 13
    E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Products under Development by Companies 14
    E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Products under Development by Universities/Institutes 17
    E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Therapeutics Assessment 19
    Assessment by Monotherapy/Combination Products 19
    Assessment by Mechanism of Action 20
    Assessment by Route of Administration 21
    Assessment by Molecule Type 23
    E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Companies Involved in Therapeutics Development 25
    Adamed Sp. z o.o. 25
    Ascentage Pharma Group Corp Ltd 26
    Astex Pharmaceuticals Inc 27
    Bristol-Myers Squibb Company 28
    F. Hoffmann-La Roche Ltd. 29
    Novartis AG 30
    Takeda Pharmaceutical Company Limited 31
    E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Drug Profiles 32
    AD-O53.2 - Drug Profile 32
    Product Description 32
    Mechanism Of Action 32
    R&D Progress 32
    ASTX-660 - Drug Profile 33
    Product Description 33
    Mechanism Of Action 33
    R&D Progress 33
    Debio-1143 - Drug Profile 35
    Product Description 35
    Mechanism Of Action 35
    R&D Progress 35
    FL-118 - Drug Profile 38
    Product Description 38
    Mechanism Of Action 38
    R&D Progress 38
    idronoxil - Drug Profile 40
    Product Description 40
    Mechanism Of Action 40
    R&D Progress 40
    LCL-161 - Drug Profile 41
    Product Description 41
    Mechanism Of Action 41
    R&D Progress 41
    SM-1200 - Drug Profile 43
    Product Description 43
    Mechanism Of Action 43
    R&D Progress 43
    Small Molecule 2 to Inhibit XIAP for Oncology - Drug Profile 44
    Product Description 44
    Mechanism Of Action 44
    R&D Progress 44
    Small Molecule to Inhibit XIAP and c-IAP for Melanoma - Drug Profile 45
    Product Description 45
    Mechanism Of Action 45
    R&D Progress 45
    Small Molecule to Inhibit XIAP for Oncology - Drug Profile 46
    Product Description 46
    Mechanism Of Action 46
    R&D Progress 46
    Small Molecules to Inhibit XIAP for Oncology - Drug Profile 47
    Product Description 47
    Mechanism Of Action 47
    R&D Progress 47
    Synthetic Peptides to Inhibit XIAP for Oncology - Drug Profile 48
    Product Description 48
    Mechanism Of Action 48
    R&D Progress 48
    T-3256336 - Drug Profile 49
    Product Description 49
    Mechanism Of Action 49
    R&D Progress 49
    E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Dormant Projects 50
    E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Discontinued Products 53
    E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Featured News & Press Releases 54
    Aug 22, 2016: Noxopharm To Initiate Radio Therapy Clinical Studies 54
    Jun 07, 2016: Debiopharm International initiates clinical Phase II study evaluating Debio 1143 in Ovarian Cancer 55
    Jun 02, 2016: FDA grants Orphan Drug Designation to Debiopharm International SA's IAP inhibitor Debio 1143 in the treatment of ovarian cancer 55
    Dec 08, 2015: EMA grants Orphan Drug Designation to Debiopharm International's IAP inhibitor Debio 1143 in the treatment of Ovarian Cancer 56
    Nov 03, 2015: Debiopharm International presents positive preliminary results from Phase 1 trials in the development of the IAP inhibitor Debio 1143 at the 27th EORTC-NCI-AACR symposium in Boston 56
    Apr 28, 2015: Camptothecin Analog FL118 Can Overcome Treatment Resistance, Outperform Approved Therapies 57
    Apr 16, 2015: Debiopharm International announces results of key oncology program, Debio 1143 at 2015 AACR Conference 58
    Dec 15, 2014: Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer 59
    Nov 18, 2014: Debiopharm Group Presents Advances Of key Oncology Product On Debio 1143 Clinical Program At The 26th EORTC-NCI-AACR Symposium In Barcelona 60
    May 28, 2014: Debiopharm tp present data on Debio 1143 at the 50th ASCO Annual Meeting 61
    Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent 61
    Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent 62
    Jun 04, 2013: Debiopharm Announces Additional Phase I Clinical Trial Evaluating Debio 1143 Combined With Chemotherapies For Patients With Selected Solid Malignancies 63
    Apr 02, 2013: Roswell Park Scientists Advance Findings about Novel, Low-Toxicity Anticancer Agent 63
    Appendix 65
    Methodology 65
    Coverage 65
    Secondary Research 65
    Primary Research 65
    Expert Panel Validation 65
    Contact Us 65
    Disclaimer 66

    List of Tables

    Number of Products under Development for, H2 2016 8
    Number of Products under Development by Therapy Area, H2 2016 9
    Number of Products under Development by Indication, H2 2016 11
    Comparative Analysis by Late Stage Development, H2 2016 12
    Comparative Analysis by Early Stage Products, H2 2016 13
    Number of Products under Development by Companies, H2 2016 14
    Products under Development by Companies, H2 2016 15
    Products under Development by Companies, H2 2016 (Contd..1) 16
    Number of Products under Investigation by Universities/Institutes, H2 2016 17
    Products under Investigation by Universities/Institutes, H2 2016 18
    Assessment by Monotherapy/Combination Products, H2 2016 19
    Number of Products by Stage and Mechanism of Action, H2 2016 20
    Number of Products by Stage and Route of Administration, H2 2016 22
    Number of Products by Stage and Molecule Type, H2 2016 24
    Pipeline by Adamed Sp. z o.o., H2 2016 25
    Pipeline by Ascentage Pharma Group Corp Ltd, H2 2016 26
    Pipeline by Astex Pharmaceuticals Inc, H2 2016 27
    Pipeline by Bristol-Myers Squibb Company, H2 2016 28
    Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 29
    Pipeline by Novartis AG, H2 2016 30
    Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 31
    Dormant Projects, H2 2016 50
    Dormant Projects (Contd..1), H2 2016 51
    Dormant Projects (Contd..2), H2 2016 52
    Discontinued Products, H2 2016 53

    List of Figures

    Number of Products under Development for, H2 2016 8
    Number of Products under Development by Top 10 Indication, H2 2016 10
    Comparative Analysis by Early Stage Products, H2 2016 13
    Assessment by Monotherapy/Combination Products, H2 2016 19
    Number of Products by Stage and Mechanism of Actions, H2 2016 20
    Number of Products by Routes of Administration, H2 2016 21
    Number of Products by Stage and Routes of Administration, H2 2016 21
    Number of Products by Molecule Types, H2 2016 23
    Number of Products by Stage and Molecule Type, H2 2016 23
    Adamed Sp. z o.o.
    Ascentage Pharma Group Corp Ltd
    Astex Pharmaceuticals Inc
    Bristol-Myers Squibb Company
    F. Hoffmann-La Roche Ltd.
    Novartis AG
    Takeda Pharmaceutical Company Limited

    Request for Sample

    Report Url http://www.reportsweb.com//e3-ubiquitin-protein-ligase-xiap-pipeline-review-h2-2016&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//e3-ubiquitin-protein-ligase-xiap-pipeline-review-h2-2016&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//e3-ubiquitin-protein-ligase-xiap-pipeline-review-h2-2016&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments